S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
3rd Massive Dollar Upheaval Has Started (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
3rd Massive Dollar Upheaval Has Started (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
3rd Massive Dollar Upheaval Has Started (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
3rd Massive Dollar Upheaval Has Started (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
NASDAQ:ACST

Acasti Pharma - ACST Stock Forecast, Price & News

$0.96
+0.05 (+5.52%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.88
$0.96
50-Day Range
$0.80
$1.02
52-Week Range
$0.80
$3.86
Volume
161,696 shs
Average Volume
80,578 shs
Market Capitalization
$42.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Acasti Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
528.3% Upside
$6.00 Price Target
Short Interest
Healthy
0.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.21mentions of Acasti Pharma in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.62) to ($0.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

371st out of 1,117 stocks

Pharmaceutical Preparations Industry

183rd out of 550 stocks

ACST stock logo

About Acasti Pharma (NASDAQ:ACST) Stock

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Acasti Pharma Stock Performance

Shares of Acasti Pharma stock traded up $0.05 during trading hours on Friday, hitting $0.96. The company's stock had a trading volume of 161,696 shares, compared to its average volume of 80,578. The firm has a fifty day moving average of $0.89 and a 200-day moving average of $1.02. The stock has a market cap of $42.49 million, a price-to-earnings ratio of -4.77 and a beta of 1.67. Acasti Pharma has a twelve month low of $0.80 and a twelve month high of $3.86.

Acasti Pharma (NASDAQ:ACST - Get Rating) last posted its earnings results on Tuesday, June 21st. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.09. On average, sell-side analysts expect that Acasti Pharma will post -0.62 earnings per share for the current fiscal year.

Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

ACST Stock News Headlines

Acasti Pharma (ACST) to Release Earnings on Thursday
Acasti Pharma Celebrates Rare Disease Day
See Why Acasti Pharma Shares Are Trading Over 20% Higher?
Acasti Pharma Announces Annual Stock Option Grants
See More Headlines
Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

ACST Company Calendar

Last Earnings
6/21/2022
Today
8/13/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACST
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+528.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-9,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$200,000.00
Book Value
$2.44 per share

Miscellaneous

Free Float
42,848,000
Market Cap
$42.49 million
Optionable
Not Optionable
Beta
1.67

Key Executives

  • Ms. Janelle D'Alvise (Age 66)
    Pres, CEO, Corp. Sec. & Director
    Comp: $428.04k
  • Dr. Pierre Lemieux M.D. (Age 57)
    Ph.D., Co-Founder, COO & Chief Scientific Officer
    Comp: $276.38k
  • Mr. Brian D. Ford CPA (Age 63)
    CA, Chief Financial Officer
    Comp: $364.82k
  • Dr. Yves Lachance Ph.D.
    VP of Quality & Compliance
  • Ms. Christine Pelletier
    Sr. Director of HR
  • Dr. George Kottayil
    Chief Operating Officer of US
  • Mr. Prashant Kohli
    VP of Commercial Operations













ACST Stock - Frequently Asked Questions

Should I buy or sell Acasti Pharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACST shares.
View ACST analyst ratings
or view top-rated stocks.

What is Acasti Pharma's stock price forecast for 2022?

1 analysts have issued 1-year target prices for Acasti Pharma's stock. Their ACST share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 528.3% from the stock's current price.
View analysts price targets for ACST
or view top-rated stocks among Wall Street analysts.

How have ACST shares performed in 2022?

Acasti Pharma's stock was trading at $1.26 at the start of the year. Since then, ACST shares have decreased by 24.2% and is now trading at $0.9550.
View the best growth stocks for 2022 here
.

When is Acasti Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our ACST earnings forecast
.

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) issued its earnings results on Tuesday, June, 21st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.09.

When did Acasti Pharma's stock split?

Acasti Pharma's stock reverse split on Tuesday, August 31st 2021. The 1-8 reverse split was announced on Tuesday, August 31st 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 31st 2021. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."

How do I buy shares of Acasti Pharma?

Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately $0.96.

How much money does Acasti Pharma make?

Acasti Pharma (NASDAQ:ACST) has a market capitalization of $42.49 million and generates $200,000.00 in revenue each year. The biopharmaceutical company earns $-9,820,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5. The official website for the company is www.acastipharma.com. The biopharmaceutical company can be reached via phone at 45-0686-4555, via email at acst@crescendo-ir.com, or via fax at 45-0687-2272.

This page (NASDAQ:ACST) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.